More credit ought to be given to the investments and inventions made by the biopharmaceutical sector—no question. But placing responsibility on the media for a perceived lack of fairness seems misplaced.
Our understanding of disease continues to expand but big hurdles remain to biopharmaceutical development. Among them is the chronic shortage of patient volunteers. There are more than 6,500 cancer clinical trials available yet only 3% of adult patients are participating. The reasons include oncologists not wanting to refer patients away from their practices, reimbursement headaches,…
The need for increased health and science literacy has never been greater. It’s a crucial gap that must be filled if we are to promote evidence-based decision making, increase productivity, enhance economic competitiveness and ensure the continuation of the democratic process.
